相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans
Wei-min Kong et al.
ACTA PHARMACOLOGICA SINICA (2020)
Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12inhibitor
Yifan Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance
Yiting Yang et al.
PHARMACEUTICS (2020)
Modulation of CYP450 Activities in Patients With Type 2 Diabetes
Sophie Gravel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P-glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover
Chao-qun Qian et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications
Frederick Zhang et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2019)
Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects
Bai-Li Song et al.
CLINICAL THERAPEUTICS (2018)
Identifying Clinically Relevant Sources of Variability: The Clopidogrel Challenge
S. Samant et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite
Dorota Danielak et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Food, gastrointestinal pH, and models of oral drug absorption
Ahmad Y. Abuhelwa et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2017)
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
Joseph M. Sweeny et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus
Liang Hu et al.
CIRCULATION (2017)
The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes
Ho-Sook Kim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Platelet aggregation in response to ADP is highly variable in normal donors and patients on anti-platelet medication
Eimear Dunne et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults
Xi-Ling Jiang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel Insights from the ELEVATE-TIMI 56 Trial
Edward T. Carreras et al.
THROMBOSIS AND HAEMOSTASIS (2016)
The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
Kazuo Umemura et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Xi-Ling Jiang et al.
CLINICAL PHARMACOKINETICS (2015)
The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions
Nontaya Nakkam et al.
DRUG METABOLISM AND PHARMACOKINETICS (2015)
A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects
Masahiko Kobayashi et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model
Jia Li et al.
CLINICAL PHARMACOKINETICS (2015)
Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus
Leonardo C. Clavijo et al.
CARDIOVASCULAR REVASCULARIZATION MEDICINE (2015)
Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics
Nassim Djebli et al.
DRUG METABOLISM AND DISPOSITION (2015)
Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans
Julie H. Oestreich et al.
AMERICAN HEART JOURNAL (2014)
Semi-Mechanistic Modelling and Simulation of Inhibition of Platelet Aggregation by Antiplatelet Agents
Hwi-yeol Yun et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2014)
CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel
Rasmus Steen Pedersen et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2014)
Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel
M. T. Holmberg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions
A. Tornio et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Aspirin Decreases Systemic Exposure to Clopidogrel Through Modulation of P-Glycoprotein But Does Not Alter Its Antithrombotic Activity
J. Oh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention
Tao Liu et al.
CORONARY ARTERY DISEASE (2014)
The Effect of CYP2C19 Genotype on the Time Course of Platelet Aggregation Inhibition After Clopidogrel Administration
Ho-Sook Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
The Influence of Genetic Polymorphism of Cyp2c19 Isoenzyme on the Pharmacokinetics of Clopidogrel and Its Metabolites in Patients With Cardiovascular Diseases
Marta Karazniewicz-Lada et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Effectiveness of Clopidogrel Dose Escalation to Normalize Active Metabolite Exposure and Antiplatelet Effects in CYP2C19 Poor Metabolizers
Richard B. Horenstein et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease
David Erlinge et al.
THROMBOSIS AND HAEMOSTASIS (2014)
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease
Paul A. Gurbel et al.
THROMBOSIS AND HAEMOSTASIS (2014)
A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions
Haifang Guo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study
Paul A. Gurbel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin
Rolf P. Kreutz et al.
PLATELETS (2013)
Carboxylesterase 1 Gene Duplication and mRNA Expression in Adipose Tissue are Linked to Obesity and Metabolic Function
Martin Friedrichsen et al.
PLOS ONE (2013)
Platelet Function Profiles in Patients with Diabetes Mellitus
Fabiana Rollini et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2013)
Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling
Guo-fu Li et al.
ACTA PHARMACOLOGICA SINICA (2012)
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants
Ronan P. Kelly et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Prediction of Clopidogrel Low Responders by a Rapid CYP2C19 Activity Test
Junichi Tazaki et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2012)
CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post-Myocardial Infarction Patients
Jean-Sebastien Hulot et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2011)
Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies
D. J. Angiolillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects
T. Simon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions
Eleanor J. Guest et al.
DRUG METABOLISM AND DISPOSITION (2011)
Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data
Helen E. Cubitt et al.
DRUG METABOLISM AND DISPOSITION (2011)
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
Dominick J. Angiolillo et al.
EUROPEAN HEART JOURNAL (2011)
High Doses of Clopidogrel to Overcome Genetic Resistance The Randomized Crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
Jean-Philippe Collet et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention A Collaborative Meta-Analysis of Individual Participant Data
Somjot S. Brar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease
Masafumi Ueno et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Comparison of Platelet Reactivity and Periprocedural Outcomes in Patients With Versus Without Diabetes Mellitus and Treated With Clopidogrel and Percutaneous Coronary Intervention
Fabio Mangiacapra et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro
Anja Zahno et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel The ONSET/OFFSET and RESPOND Genotype Studies
Udaya S. Tantry et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2010)
Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling Two Cytochrome P450 3A4 Substrates Coadministered with Ketoconazole or Verapamil
Nathalie Perdaems et al.
CLINICAL PHARMACOKINETICS (2010)
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Miho Kazui et al.
DRUG METABOLISM AND DISPOSITION (2010)
The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy
Anand Singla et al.
AMERICAN HEART JOURNAL (2009)
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Christoph Varenhorst et al.
EUROPEAN HEART JOURNAL (2009)
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: Clinical significance and molecular basis
Hao-Jie Zhu et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance
K. A. Kim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease
A. J. Peace et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects
K. Umemura et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
General approach for the calculation of tissue to plasma partition coefficients
Walter Schmitt
TOXICOLOGY IN VITRO (2008)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prediction of intestinal first-pass drug metabolism
Jiansong Yang et al.
CURRENT DRUG METABOLISM (2007)
Impact of P-glycoprotein on clopidogrel absorption
Dirk Taubert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery
N Parrott et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
DJ Angiolillo et al.
DIABETES (2005)
The difference between clopidogrel responsiveness and posttreatment platelet reactivity
WM Samara et al.
THROMBOSIS RESEARCH (2005)
CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity
E Garcia-Martin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Evaluation of gut motility in type II diabetes by the radiopaque marker method
M Iida et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2000)
分享论文
